AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%) (%)
Form 6-K / 20-F Therapy Area Product Sales Table
Latest, Q2 2026
6.0%
Period ended Jun 30, 2026
Change on a year earlier
+46.0 pts
-40.0% in Q2 2025
History
16 quarters
Since Q3 2022
Sources
16
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 6.0% | +46.0 pts | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 55.0% | +122.0 pts | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | -82.0% | -38.0 pts | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | -57.0% | -80.0 pts | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | -40.0% | -95.0 pts | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | -67.0% | +19.0 pts | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | -44.0% | +31.0 pts | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 23.0% | +100.0 pts | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 55.0% | +144.0 pts | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | -86.0% | -24.0 pts | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | -75.0% | -68.0 pts | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | -77.0% | -79.0 pts | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | -89.0% | – | Form 6-K FY2023Q2 Earnings Release ↗ |
| Q1 2023 | Mar 31, 2023 | -62.0% | – | Form 6-K FY2023Q1 Earnings Release ↗ |
| Q4 2022 | Dec 31, 2022 | -7.0% | – | Form 6-K FY2022Q4 Earnings Release ↗ |
| Q3 2022 | Sep 30, 2022 | 2.0% | – | Form 6-K FY2022Q3 Earnings Release ↗ |
Cite this data
StockData. (2026). AstraZeneca Vaccines & Immune Therapies / Infectious Disease (V&I / ID) — Established RoW YoY CER (%) (%), quarterly Q3 2022–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta_vi_erow_cer_yoy
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.